Storia in 2 fonti

Next-Gen BCL2 Inhibitor Approved for Aggressive Lymphoma

Sonrotoclax (Beqalzi) indicated for relapsed or refractory mantle cell lymphoma

Raccontata da

medpagetoday.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo1 mesi fa

Next-Gen BCL2 Inhibitor Approved for Aggressive Lymphoma

Sonrotoclax (Beqalzi) indicated for relapsed or refractory mantle cell lymphoma

originale

endpoints.news1 mesi fa

Updated: BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta

BeOne Medicines has clinched US accelerated approval for its drug sonrotoclax in a rare but aggressive form of blood cancer, where AbbVie and Genentech’s Venclexta is used off-label.

Leggi questa versione → originale

Timeline cronologica

mercoledì 13 maggio 2026·medpagetoday.com
Next-Gen BCL2 Inhibitor Approved for Aggressive Lymphoma
Sonrotoclax (Beqalzi) indicated for relapsed or refractory mantle cell lymphoma
giovedì 14 maggio 2026·endpoints.news
Updated: BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta
BeOne Medicines has clinched US accelerated approval for its drug sonrotoclax in a rare but aggressive form of blood cancer, where AbbVie and Genentech’s Venclexta is used…